Drawing on a SARS-CoV-2 vaccine trial in a Latinx community in San Diego, we show how trial designs fail to redress structural racism and may introduce new harms While important, trial diversity alone cannot redress entrenched inequities that affect Black, Indigenous, and People of Color (BIPOC) communities
Why Calls to Diversify Trial Populations Fall Short